We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+9.58%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$155M
AUM Growth
+$7.79M
Cap. Flow
-$3.04M
Cap. Flow %
-1.96%
Top 10 Hldgs %
83.08%
Holding
58
New
5
Increased
5
Reduced
13
Closed
4

Top Buys

Rank Stock Value
1
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$714K
2
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$568K
3
OPK icon
Opko Health
OPK
+$552K
4
ARVN icon
Arvinas
ARVN
+$494K
5
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$408K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$1.41M
2
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$815K
3
CFRX
ContraFect Corporation
CFRX
+$576K
4
VCYT icon
Veracyte
VCYT
+$551K
5
OVV icon
Ovintiv
OVV
+$441K

Sector Composition

Rank Sector Weight
1 Healthcare 96.81%
2 Energy 2.32%
3 Consumer Staples 0.25%
4 Industrials 0.16%
5 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$60M 38.71%
670,181
-16,000
-2% -$1.41M
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$50.1M 32.35%
218,380
– –
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$5.9M 3.81%
48,000
-2,000
-4% -$227K
QDEL icon
4
QuidelOrtho
QDEL
$1.19B
$2.21M 1.43%
33,975
– –
VNDA icon
5
Vanda Pharmaceuticals
VNDA
$327M
$2.02M 1.3%
88,000
– –
ARRY
6
DELISTED
Array Biopharma Inc
ARRY
$1.95M 1.26%
128,000
– –
OVV icon
7
Ovintiv
OVV
$16.2B
$1.68M 1.09%
25,660
-6,800
-21% -$441K
CFRX
8
DELISTED
ContraFect Corporation
CFRX
$1.65M 1.07%
996
-348
-26% -$576K
OXFD
9
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$1.63M 1.05%
100,303
-57,000
-36% -$815K
VRML
10
DELISTED
Vermillion, Inc.
VRML
$1.58M 1.02%
2,232,933
– –
SLNO
11
DELISTED
Soleno Therapeutics
SLNO
$1.42M 0.92%
43,773
-1,456
-3% -$52.9K
ATRA icon
12
Atara Biotherapeutics
ATRA
$75.6M
$1.41M 0.91%
1,360
– –
EQT icon
13
EQT Corp
EQT
$31B
$1.38M 0.89%
57,498
-12,859
-18% -$355K
CMTA
14
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$1.36M 0.88%
122,000
+54,000
+79% +$568K
SIEN
15
DELISTED
Sientra, Inc.
SIEN
$1.27M 0.82%
5,330
-1,000
-16% -$220K
ALBO
16
DELISTED
Albireo Pharma Inc
ALBO
$1.25M 0.81%
38,000
– –
ARNA
17
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.01M 0.65%
22,000
-3,000
-12% -$122K
MASI
18
DELISTED
Masimo
MASI
$996K 0.64%
8,000
– –
WMGI
19
DELISTED
Wright Medical Group Inc
WMGI
$871K 0.56%
30,000
– –
KPTI icon
20
Karyopharm Therapeutics
KPTI
$216M
$852K 0.55%
3,333
– –
GTHX
21
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$784K 0.51%
15,000
-7,000
-32% -$382K
BIIB icon
22
Biogen
BIIB
$30.4B
$707K 0.46%
2,000
– –
CORT icon
23
Corcept Therapeutics
CORT
$9.72B
$701K 0.45%
50,000
– –
DRNA
24
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$687K 0.44%
45,000
– –
XLRN
25
DELISTED
Acceleron Pharma
XLRN
$687K 0.44%
12,000
– –
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2018 Portfolio in Review

As of Q3 2018, Birchview Capital held 58 positions worth $155M, up 5.3% from $147M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Birchview Capital's Q3 2018 filing shows 5 new, 5 increased, 13 reduced and 4 closed positions. Its largest new stake was Dova Pharmaceuticals, Inc. Common Stock: 30,000 shares worth $629K. The largest sale was Celgene Corp, an estimated $1.41M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q3 2018 buy was Dova Pharmaceuticals, Inc. Common Stock: 30,000 shares worth $629K.
  • Birchview Capital added most to Clementia Pharmaceuticals Inc. in Q3 2018, an estimated $568K increase.
  • Birchview Capital's biggest Q3 2018 reduction was Celgene Corp, cutting an estimated $1.41M.
  • Birchview Capital fully exited Aptinyx Inc. Common Stock in Q3 2018, selling an estimated $242K.
  • Birchview Capital's ten largest holdings make up 83% of its $155M portfolio in Q3 2018.
  • Birchview Capital opened 5 new positions and closed 4 in Q3 2018.
  • Birchview Capital's portfolio value rose 5.3% quarter-over-quarter to $155M.

Based on Birchview Capital's 13F filing for Q3 2018, filed 1 Nov 2018.